Nilotinib and LDE225 in the Treatment of Chronic or Accelerated Phase Myeloid Leukemia in Patients Who Developed Resistance to Prior Therapy

NCT01456676 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

11

Enrollment

INDUSTRY

Sponsor class

Conditions

Philadelphia Chromosome Positive Chronic Myelogenous Leukemia

Interventions

DRUG: Nilotinib + LDE225

Sponsor

Novartis Pharmaceuticals